Quantcast
Last updated on April 17, 2014 at 13:30 EDT

Latest Michael Mullan Stories

2012-11-27 12:27:15

GLEN ALLEN, Va., Nov. 27, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces that new anatabine research has been accepted by and published online in the European Journal of Pharmacology. In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer's disease, inflammation in the blood in mice, and inflammation induced in human blood once removed from the body. This peer-reviewed...

2012-10-17 11:23:53

GLEN ALLEN, Va., Oct. 17, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented research this week showing that anatabine supplementation reduces the pathology and signs in an animal model of Alzheimer's disease. The findings were presented in New Orleans, Louisiana, at Neuroscience 2012, the 42nd annual meeting of the Society for...

2012-10-16 11:25:42

GLEN ALLEN, Va., Oct. 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that earlier in the week scientists from its research partner, the Roskamp Institute, presented results of its recent research showing that anatabine supplementation significantly reduces central and peripheral inflammation and neurological injury in an animal model of multiple sclerosis (MS). The findings were presented in New...

2012-10-15 11:28:25

GLEN ALLEN, Va., Oct. 15, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented new research yesterday and today indicating that supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement, has the potential to alleviate the negative consequences of traumatic brain injury (TBI). These...

2012-08-23 06:25:34

GLEN ALLEN, Va., Aug. 23, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary Rock Creek Pharmaceuticals Inc., announced today that the Alzheimer's study of the company's dietary supplement Anatabloc(® )has screened and enrolled its first patient. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The Alzheimer's study, entitled, "A Three Month, Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to...

2012-05-08 06:31:06

GLEN ALLEN, Va., May 8, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., announces that it has received important new research findings from its research partner, The Roskamp Institute of Sarasota, Florida. The Institute has completed a successful animal study of nutritional supplementation with Rock Creek's specially formulated anatabine (patent pending), in an animal model of multiple sclerosis. The Roskamp...

2012-01-11 09:54:00

GLEN ALLEN, Va., Jan. 11, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) - A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss. Dr. Paul Newhouse, a professor of psychiatry at Vanderbilt University Medical Center, led a study which showed that six months of nicotine patch treatment among patients who had mild cognitive impairment - often a precursor to Alzheimer's disease - had a...

2011-10-04 13:35:00

GLEN ALLEN, Va., Oct. 4, 2011 /PRNewswire/ -- Star Scientific, Inc. (Nasdaq: CIGX) reports today the publication of the first peer-reviewed article on the in-vitro and in-vivo activity of anatabine in Alzheimer's Disease. The article is authored by scientists at the Roskamp Institute and is electronically published in the European Journal of Pharmacology (2011 Sept 19). It states that anatabine lowers Alzheimer's A-beta production in-vitro and in-vivo. (Logo:...

2010-10-07 09:25:00

SARASOTA, Fla., Oct. 7 /PRNewswire-USNewswire/ -- Today the Roskamp Institute said that it is pleased to announce that it will soon begin clinical trials of RCP-006, a compound found in tobacco, for the treatment of Alzheimer's disease. The compound was developed by Rock Creek Pharmaceuticals, a subsidiary of Star Scientific in Virginia, and made available to Roskamp through its affiliate, SRQ Bio, LLC. In laboratory tests with cells, the compound, RCP-006, a natural product, inhibits...

2010-09-27 10:55:00

SARASOTA, Fla., Sept. 27 /PRNewswire-USNewswire/ -- Scientists at the Roskamp Institute in Sarasota, Florida, have shown that mice that naturally develop Alzheimer's are able to ward off the growth of brain cancer. In a series of experiments published in the Journal of Neuroscience, they showed that mice that spontaneously develop Alzheimer's Disease are able to dramatically reduce the growth of a human brain cancer. Brain cancers affect 612,000 people in the United States and are...